Marius Hoeper, MD, discusses the recently FDA-approved pulmonary arterial hypertension (PAH) treatment sotatercept, discussing its mechanism of action, possible cost implications, and potential advantages and disadvantages compared with existing foundational therapies. Learn more about sotatercept with this episode: https://bit.ly/3X7qDqZ #ManagedCare #PulmonaryHypertension
AJMC - The American Journal of Managed Care’s Post
More Relevant Posts
-
Have you ever heard of Pulmonary Artery Hypertension? Essentially, pulmonary artery hypertension (PAH) is a complex condition involving high blood pressure in the arteries that supply blood to the lungs. This increased pressure can strain the heart and lead to serious complications over time. It's often categorized as a type of pulmonary hypertension, which broadly refers to elevated pressure in the pulmonary arteries. Swipe to learn more about the various ways the condition can be treated. ((Disclaimer: This is only for educational purposes. please consult a doctor to understand what treatment is apt for you)) #pulmonaryarteryhypertension #therapy #regulatorycompliance #medicalsolutions #pulmonary #medicaladvice #pharmaceuticalindustry #heartdisease #medicalinnovations
To view or add a comment, sign in
-
Together with CarelonRx, we assessed the rates of lipid testing and treatment target attainment among patients with ASCVD and/or T2DM initiating lipid lowering therapies following the 2018 Multi-society Guideline on the Management of Blood Cholesterol (AHA/ACC). See abstract #198 recently presented at the #NLASessions to learn more: https://ow.ly/HglJ50S7a8k.
To view or add a comment, sign in
-
-
Idiopathic Pulmonary Fibrosis Market Size, Industry, Trends, Report, 2023-2032 Global #idiopathic #pulmonary #fibrosis market size is expected at $4.89 Bn by 2027 at a growth rate of 5.9%. Read More @https://lnkd.in/giUVRx_W #marketresearch #marketintelligence #marketreport #industryanalysis #TheBusinessResearchCompany #TBRC #GlobalMarketModel
To view or add a comment, sign in
-
Missed it? A replay of our latest #PVRIDigital webinar on 'Enhancing drug development for paediatric pulmonary hypertension: an integrative perspective' is now available. Watch here: https://lnkd.in/d_pXeXyx
To view or add a comment, sign in
-
-
Finally this task finished .interesting multicentric paper that showed endovascular unit experience in treatment of venous hypertension in dialysis patients #venoushypertension #hemodialysis #endovascular
To view or add a comment, sign in
-
Treatment of CKD Anemia: Stepwise algorithm https://lnkd.in/dAjKW5rT
Anaemia in CKD—treatment standard
academic.oup.com
To view or add a comment, sign in
-
Pulmonary arterial hypertension (PAH) is a rare, progressive disorder characterized by high blood pressure in the lung’s pulmonary arteries. With new approvals in this space, payers will need to prioritize identifying patient populations and ensuring access while mitigating costs. Download the Magellan Rx report for insights on the PAH treatment landscape, recent and expected drug approvals, payer strategies and more to help you make the best decisions for your business and members. Download the report here: https://bit.ly/3YeppL3
To view or add a comment, sign in
-
-
Severe Intracranial hypertension secondary to transverse-sigmoid sinus junction stenosis, treated by Angioplasty alone followed by low dose anti-coagulation. Serial Fundus examination showing resolution of papilledema. Patient showed improvement in vision on table!! #strokespecialist #strokeprevention #stroketreatment #strokeawareness #strokecare #strokerehabilitation #lifestylemedicine #functionalmedicine #preventivemedicine
To view or add a comment, sign in
-
-
European Society of Hypertension (ESH) Conference, is scheduled to take place from May 31st to June 3rd. The ESH Conference promises to be a pivotal event in the field of hypertension management, offering a platform for leading experts to share the latest research, advancements, and best practices. The conference will feature several major sessions that are of particular interest: 1. ESH 2024 Clinical Practice Guidelines 2. ESC-HFA JOINT SESSION: Hypertension and Heart Failure Management Update 3. ESH guidelines 2023: a new light on beta-blockers in hypertension 4. Beta-blockers in hypertension and CVD: similar or different? 5. True Resistant Hypertension Treatment in 2024 Target Blood Pressure controversies Stay tuned with Carbon Brand Solutions for more medical updates! #medicalupdate #medicalupdates #medicalnews #pharmaupdate #pharmaupdates #pharmaceuticalupdate #pharmaceuticalupdates #doctorsupdate #doctorsupdates #esh #europeansocietyofhypertention #hypertention #hypertentionupdate #medicalconference #medicalconferences #pharmaconference #pharmeceuticalconference #pharmaconferences #pharmeceuticalconferences #hypertentionupdates #hypertentionnews #carbonbrandsolutions
To view or add a comment, sign in
-
-
Gout is a type of painful arthritis. Symptoms such as pain and swelling can recur during gout attacks. Clinically, Allopurinol is one of the most commonly used medications. Allopurinol is suitable for patients with recurrent or chronic gout, as it can alleviate symptoms and reduce the formation of uric acid kidney stones. Additionally, Allopurinol is commonly used for both primary and secondary hyperuricemia, especially for those with kidney function issues. Want to learn about the treatment principles of Allopurinol and its broader clinical applications? Please visit our website: https://lnkd.in/gVFqA2gX #TJCY #Allopurinol #AntipyreticAnalgesic #Gout #PainfulArthritis #API #Intermediate #Drugs #Medicine
To view or add a comment, sign in
-